ClinicalTrials.gg

Program

EC5026

Also written as “EC5026 oral tablet” and “EC5026 oral capsule”.

Its studies are mostly in Spinal Cord Injuries · Renal Insufficiency, Chronic, led by EicOsis Human Health.

Furthest: phase 2, since Aug 19, 20256 company-led studies, 3 open or runningNext primary completion: Dec 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
EicOsis Human Health63 open or runningphase 2since Aug 19, 2025Jan 6, 2020Dec 2026phase 2 · NCT07142044

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 6, 2020First study: phase 1 study in Healthy AdultsFirst studyNCT04228302 · 40 enrolled · United States
  2. May 26, 2021Phase 1 study in Healthy AdultsNCT04908995 · 18 enrolled · United States
  3. Oct 12, 2023Phase 1 study in Healthy SubjectsNCT06089837 · 16 enrolled · New Zealand
  4. May 24, 2024Phase 1 study in Spinal Cord InjuriesNCT06438471 · 36 planned · United States
  5. Aug 19, 2025Phase 2 study in Parkinson's Disease (PD)NCT07142044 · 18 planned · United States
  6. Jul 3, 2026Phase 1 study in Renal Insufficiency, ChronicNCT07694544 · 18 planned · United States

Ahead

  1. Dec 2026Primary completion: phase 2 study in Parkinson's Disease (PD)NCT07142044
  2. Dec 31, 2026Primary completion: phase 1 study in Renal Insufficiency, ChronicNCT07694544
  3. Dec 2027Primary completion: phase 1 study in Spinal Cord InjuriesNCT06438471

TargetBeta

EPHX2 →read by rule
“The study drug, EC5026, is an orally bioavailable inhibitor of an enzyme, soluble epoxide hydrolase (sEH), that is being developed as a first-in-class anti-inflammatory agent.”study text, by rule · the study

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07694544Renal Insufficiency, Chronic · United States1RecruitingDec 31, 202618
NCT07142044Parkinson's Disease (PD) · United States2RecruitingDec 202618
NCT06438471Spinal Cord Injuries · United States1RecruitingDec 202736
NCT06089837Healthy Subjects · New Zealand1CompletedMar 13, 202416
NCT04908995Healthy Adults · United States1CompletedMay 12, 202118
NCT04228302Healthy Adults · United States1CompletedJul 7, 202040

How it is read

Names in the registry

  • “EC5026 oral tablet”, 5 entries
  • “EC5026 oral capsule”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.